RecruitingPhase 1NCT07179679

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

Studying Multiple myeloma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Intervention: TQB2934 injection (subcutaneous injection)(drug)
Enrollment: 42 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2025 – 2028

Study locations (14)

Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
The Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
Nanjing Drum Tower hospital, Nanjing, Jiangsu, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Nanchang University First Affiliated Hospital, Nanchang, Jiangxi, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Heze Municipal Hospital, Heze, Shandong, China
Zhongshan Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
Tianjin People's Hospital, Tianjin, Tianjin Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07179679 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials